Peter  Salzmann net worth and biography

Peter Salzmann Biography and Net Worth

CEO of Immunovant

Peter Salzmann, M.D., M.B.A, is the Chief Executive Officer of Immunovant and a member of our board of directors. From November 2018 to June 2019, he served as a Global Brand Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and oversaw Phase 2 and 3 clinical trial execution. From March 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.

What is Peter Salzmann's net worth?

The estimated net worth of Peter Salzmann is at least $29.11 million as of October 16th, 2024. Dr. Salzmann owns 994,789 shares of Immunovant stock worth more than $29,107,526 as of October 31st. This net worth evaluation does not reflect any other investments that Dr. Salzmann may own. Additionally, Dr. Salzmann receives an annual salary of $1,020,000.00 as CEO at Immunovant. Learn More about Peter Salzmann's net worth.

How old is Peter Salzmann?

Dr. Salzmann is currently 56 years old. There are 6 older executives and no younger executives at Immunovant. Learn More on Peter Salzmann's age.

What is Peter Salzmann's salary?

As the CEO of Immunovant, Inc., Dr. Salzmann earns $1,020,000.00 per year. Learn More on Peter Salzmann's salary.

How do I contact Peter Salzmann?

The corporate mailing address for Dr. Salzmann and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Peter Salzmann's contact information.

Has Peter Salzmann been buying or selling shares of Immunovant?

During the past quarter, Peter Salzmann has sold $393,682.65 in shares of Immunovant stock. Most recently, Peter Salzmann sold 9,095 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $28.79, for a transaction totalling $261,845.05. Following the completion of the sale, the chief executive officer now directly owns 994,789 shares of the company's stock, valued at $28,639,975.31. Learn More on Peter Salzmann's trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, insiders at the sold shares 36 times. They sold a total of 204,388 shares worth more than $6,214,884.80. The most recent insider tranaction occured on October, 23rd when insider Mark S Levine sold 4,361 shares worth more than $128,780.33. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 10/23/2024.

Peter Salzmann Insider Trading History at Immunovant

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/16/2024Sell9,095$28.79$261,845.05994,789View SEC Filing Icon  
10/9/2024Sell4,460$29.56$131,837.601,003,884View SEC Filing Icon  
7/17/2024Sell8,685$29.69$257,857.651,023,412View SEC Filing Icon  
7/9/2024Sell4,619$28.06$129,609.141,032,097View SEC Filing Icon  
5/22/2024Sell16,163$29.65$479,232.951,036,716View SEC Filing Icon  
4/17/2024Sell34,079$29.06$990,335.741,052,879View SEC Filing Icon  
4/9/2024Sell4,807$31.18$149,882.261,086,958View SEC Filing Icon  
1/5/2024Sell3,824$38.59$147,568.16944,685View SEC Filing Icon  
11/22/2023Sell16,217$32.78$531,593.26948,509View SEC Filing Icon  
10/5/2023Sell5,239$36.24$189,861.36964,726View SEC Filing Icon  
8/30/2023Sell56,774$22.02$1,250,163.48969,965View SEC Filing Icon  
8/14/2023Sell103,058$21.42$2,207,502.361,026,739View SEC Filing Icon  
8/7/2023Sell101,339$21.73$2,202,096.471,129,797View SEC Filing Icon  
7/12/2023Sell3,233$19.73$63,787.091,231,136View SEC Filing Icon  
4/18/2023Sell3,395$15.27$51,841.651,234,369View SEC Filing Icon  
1/11/2023Sell4,021$16.80$67,552.80993,932View SEC Filing Icon  
10/13/2022Sell2,793$9.18$25,639.74997,953View SEC Filing Icon  
9/28/2022Sell1,605$4.67$7,495.351,000,746View SEC Filing Icon  
8/30/2022Sell1,644$5.83$9,584.521,002,351View SEC Filing Icon  
7/27/2022Sell1,528$4.27$6,524.56552,731View SEC Filing Icon  
6/29/2022Sell1,376$4.02$5,531.52554,259View SEC Filing Icon  
5/24/2022Sell1,471$3.79$5,575.09555,635View SEC Filing Icon  
4/27/2022Sell1,622$4.72$7,655.84557,106View SEC Filing Icon  
3/24/2022Sell19,227$5.90$113,439.30558,728View SEC Filing Icon  
See Full Table

Peter Salzmann Buying and Selling Activity at Immunovant

This chart shows Peter Salzmann's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $29.26
Low: $29.25
High: $30.30

50 Day Range

MA: $29.97
Low: $28.02
High: $34.03

2 Week Range

Now: $29.26
Low: $24.67
High: $45.58

Volume

626,428 shs

Average Volume

1,087,596 shs

Market Capitalization

$4.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66